ClinicalTrials.gg
CompletedNCT00654303Updated Mar 16, 2009

OLE Study to Evaluate Safety / Efficacy of ZD4522

A Phase 3 interventional study of Rosuvastatin in Hypercholesterolaemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Planned enrollment
6th of 57
3,500 · median 203
Started
1999
the only one that year
Phase 3
33 of 59
none open now
Registered
21st of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 6th largest by planned enrollment of the 57 interventional ones that give a count, is the only one that started in 1999, is one of 33 in phase 3, and was the 21st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to assess the long term safety of Crestor.

03

Conditions studied

  • Hypercholesterolaemia

Keywords

  • Cholesterol
  • Hypercholesterolaemia
  • Statins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of previous Crestor study as listed in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding women, or not using appropriate .
  • Abnormal lab values as listed in the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3,500 participants (estimated)

Study arms

  • Experimental
    1

    Rosuvastatin

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Safety, as determined by adverse events, laboratory data, physical examination and ECG.

    Time frame: 12 weekly

Secondary outcomes

  1. Success in achieving goals for Cholesterol levels

    Time frame: 12 weekly

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1999 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2008
First posted
Apr 7, 2008
Start
Aug 1999
CompletionActual
Feb 2005
Last update
Mar 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00654303
Lead sponsor
AstraZeneca
First posted
Apr 7, 2008
Start date
Aug 1999
Completion
Feb 2005
Last update
Mar 16, 2009

Study contacts

Elinor Miller, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion